Avandia has no increased overall heart risk
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines – Clinical trial results presented at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.